scholarly journals Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study

2021 ◽  
pp. 1-11
Author(s):  
Walburga Yvonne Joko-Fru ◽  
Mirko Griesel ◽  
Nikolaus Christian Simon Mezger ◽  
Lucia Hämmerl ◽  
Tobias Paul Seraphin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Relative Survival ◽  
Population Level ◽  
Population Based ◽  
Hormone Receptor Status ◽  
Sub Saharan Africa ◽  
Receptor Status ◽  
Sub Saharan ◽  
The Impact

Background: Breast cancer (BC) is the most common cancer in sub-Saharan Africa (SSA). However, little is known about the actual therapy received by women with BC and their survival outcome at the population level in SSA. This study aims to describe the cancer-directed therapy received by patients with BC at the population level in SSA, compare these results with the NCCN Harmonized Guidelines for SSA (NCCN Harmonized Guidelines), and evaluate the impact on survival. Methods: Random samples of patients with BC (≥40 patients per registry), diagnosed from 2009 through 2015, were drawn from 11 urban population–based cancer registries from 10 countries (Benin, Congo, Cote d’Ivoire, Ethiopia, Kenya, Mali, Mozambique, Namibia, Uganda, and Zimbabwe). Active methods were used to update the therapy and outcome data of diagnosed patients (“traced patients”). Excess hazards of death by therapy use were modeled in a relative survival context. Results: A total of 809 patients were included. Additional information was traced for 517 patients (63.8%), and this proportion varied by registry. One in 5 traced patients met the minimum diagnostic criteria (cancer stage and hormone receptor status known) for use of the NCCN Harmonized Guidelines. The hormone receptor status was unknown for 72.5% of patients. Of the traced patients with stage I–III BC (n=320), 50.9% received inadequate or no cancer-directed therapy. Access to therapy differed by registry area. Initiation of adequate therapy and early-stage diagnosis were the most important determinants of survival. Conclusions: Downstaging BC and improving access to diagnostics and care are necessary steps to increase guideline adherence and improve survival for women in SSA. It will also be important to strengthen health systems and facilities for data management in SSA to facilitate patient follow-up and disease surveillance.

scholarly journals Association between Polyphenol Intake and Breast Cancer Risk by Menopausal and Hormone Receptor Status

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 994
Author(s):  
Facundo Vitelli-Storelli ◽  
Raul Zamora-Ros ◽  
Antonio J. Molina ◽  
Tania Fernández-Villa ◽  
Adela Castelló ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Case Control Study ◽  
Menopausal Status ◽  
Population Based ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Types ◽  
Polyphenol Intake ◽  
Control Study

There is limited evidence of phenolic compounds acting as protective agents on several cancer types, including breast cancer (BC). Nevertheless, some polyphenol classes have not been investigated and there is a lack of studies assessing the effect on menopausal status and hormone receptor status as influenced by these compounds. The objective of this study is to evaluate the association between the intake of all polyphenol classes in relation to the BC risk by menopausal and hormone receptor status. We used data from a population-based multi-case-control study (MCC-Spain) including 1472 BC cases and 1577 controls from 12 different regions of Spain. The odds ratios (ORs) with 95% CI were calculated using logistic regression of mixed effects by quartiles and log2 of polyphenol intakes (adjusted for the residual method) of overall BC, menopausal and receptor status. No associations were found between total intake of polyphenols and BC risk. However, inverse associations were found between stilbenes and all BC risk (ORQ4 vs. Q1: 0.70, 95%CI: 0.56–0.89, Ptrend = 0.001), the consumption of hydroxybenzaldehydes (ORQ4 vs. Q1: 0.75, 95%CI: 0.59–0.93, Ptrend = 0.012) and hydroxycoumarins (ORQ4 vs. Q1: 0.73, 95%CI: 0.57–0.93; Ptrend = 0.005) were also inversely associated. The intake of stilbenes, hydroxybenzaldehydes and hydroxycoumarins can contribute to BC reduction risk on all menopausal and receptor statuses.

scholarly journals Hormone receptor status may impact the survival benefit of surgery in stage IV breast cancer: a population-based study

Oncotarget ◽  
2016 ◽  
Vol 7 (43) ◽  
pp. 70991-71000 ◽  
Author(s):  
Yinuo Tan ◽  
Xiaofen Li ◽  
Haiyan Chen ◽  
Yeting Hu ◽  
Mengjie Jiang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Survival Benefit ◽  
Stage Iv ◽  
Population Based ◽  
Hormone Receptor Status ◽  
Population Based Study ◽  
Receptor Status ◽  
Stage Iv Breast Cancer

scholarly journals Prognostic value of morphology and hormone receptor status in breast cancer – a population-based study

2004 ◽  
Vol 91 (7) ◽  
pp. 1263-1268 ◽  
Author(s):  
C Allemani ◽  
M Sant ◽  
F Berrino ◽  
T Aareleid ◽  
G Chaplain ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Prognostic Value ◽  
Population Based ◽  
Hormone Receptor Status ◽  
Population Based Study ◽  
Receptor Status

scholarly journals Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Matteo Lambertini ◽  
Marcello Ceppi ◽  
Anne-Sophie Hamy ◽  
Olivier Caron ◽  
Philip D. Poorvu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Young Patients ◽  
Disease Free Survival ◽  
Distant Recurrence ◽  
Hormone Receptor Status ◽  
Second Primary ◽  
Clinical Behavior ◽  
Receptor Status ◽  
The Impact

AbstractYoung breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [HR−]) on clinical behavior and outcomes of mBRCA BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included mBRCA patients diagnosed, between January 2000 and December 2012, with stage I–III invasive early BC at age ≤40 years. From 30 centers worldwide, 1236 young mBRCA BC patients were included. Among 808 and 428 patients with mBRCA1 or mBRCA2, 191 (23.6%) and 356 (83.2%) had HR+tumors, respectively (P < 0.001). Median follow-up was 7.9 years. Second primary BC (P = 0.009) and non-BC malignancies (P = 0.02) were more frequent among mBRCA1 patients while distant recurrences were less frequent (P = 0.02). Irrespective of hormone receptor status, mBRCA1 patients had worse disease-free survival (DFS; adjusted HR = 0.76, 95% CI = 0.60–0.96), with no difference in distant recurrence-free interval (DRFI) and overall survival (OS). Patients with HR+ disease had more frequent distant recurrences (P < 0.001) and less frequent second primary malignancies (BC: P = 0.005; non-BC: P = 0.18). No differences in DFS and OS were observed according to hormone receptor status, with a tendency for worse DRFI (adjusted HR = 1.39, 95% CI = 0.94–2.05) in patients with HR+ BC. Type of mBRCA gene and hormone receptor status strongly impact BC clinical behavior and outcomes in mBRCA young patients. These results provide important information for patients’ counseling on treatment, prevention, and surveillance strategies.

A detailed analysis of the risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 562-562
Author(s):  
J. Houghton
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Distant Recurrence ◽  
Hormone Receptor Status ◽  
Nodal Involvement ◽  
Receptor Status ◽  
Factors Influencing ◽  
The Impact

562 Background: The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC; ISRCTN18233230 ) trial compared the efficacy and safety of 5 years’ anastrozole, tamoxifen, or combination as adjuvant therapy for 9366 postmenopausal women with early invasive breast cancer. Here, risk factors influencing local and distant recurrences during the trial, independent of trial treatment, are assessed. Methods: The influence of standard baseline factors such as hormone receptor status, nodal involvement, tumor size, grade and age were evaluated on both local and distant recurrence rates. The use of other treatments (adjuvant chemotherapy, radiotherapy) and surgical status (mastectomy and axillary surgery) were also included. In addition, weight, body mass index, hysterectomy and prior hormone- replacement therapy were added. Cox models were used to analyze events by prognostic factors, and subsequently adjusted by country, before the production of confirmatory models. Results: For both local and distant recurrence, the highest risk correlated with poorer tumor differentiation, larger tumor size, increased nodal involvement and a negative hormone receptor status (see table ). While surgical status also affected the risk of developing a recurrence, previous treatments were less important, but residence in the USA showed a significant advantage. No association was seen with hysterectomy or weight for any recurrence. Conclusions: Although the pattern of risk varied for local and distant recurrence, tumor grade, size, and nodal involvement were the strongest risk factors for both. In comparison, the impact of previous treatments on hazard risk was lower. These data from a large international clinical trial confirm that women with less differentiated or larger tumors, and those with involved nodes, are at an increased risk of recurrence. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document